Tarsus Pharmaceuticals (TARS) Income from Continuing Operations (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Income from Continuing Operations of 6928000.0 for Q1 2026, up 72.33% year-over-year from 4020166.67 in Q1 2025, and down 22.68% quarter-over-quarter from 5647000.0 in Q4 2025.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 6928000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 72.33% year-over-year to 6928000.0; the TTM figure through Mar 2026 stood at 148948000.0 (down 44.76% YoY), while the FY2025 annual figure was 66418000.0, up 42.52% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6928000.0, down from 5647000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 5471000.0 in Q2 2022, with the low at 123690000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 23343000.0 (2023), against an average of 28519000.0.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations sank 474.12% in 2023, then soared 75.54% in 2025.
- Tarsus Pharmaceuticals' Income from Continuing Operations stood at 13626000.0 in 2022, then sank by 210.57% to 42318000.0 in 2023, then surged by 45.45% to 23086000.0 in 2024, then jumped by 75.54% to 5647000.0 in 2025, then slipped by 22.68% to 6928000.0 in 2026.
- Business Quant data shows TARS's Income from Continuing Operations at 6928000.0 in Q1 2026, 5647000.0 in Q4 2025, and 12683000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | -21.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.08 Mn |
| Mar 31, 2026 | -6.93 Mn |
| Dec 31, 2025 | -6.24 Mn |
| Sep 30, 2025 | -12.68 Mn |
| Jun 30, 2025 | -20.20 Mn |
| Mar 31, 2025 | -25.04 Mn |
| Dec 31, 2024 | -23.09 Mn |
| Sep 30, 2024 | -23.49 Mn |
| Jun 30, 2024 | -31.28 Mn |
| Mar 31, 2024 | -35.55 Mn |
| Dec 31, 2023 | -42.46 Mn |
| Sep 30, 2023 | -38.95 Mn |
| Jun 30, 2023 | -31.41 Mn |
| Mar 31, 2023 | -23.34 Mn |
| Dec 31, 2022 | -13.63 Mn |
| Sep 30, 2022 | -22.47 Mn |
| Jun 30, 2022 | -5.47 Mn |
| Mar 31, 2022 | -19.84 Mn |
| Dec 31, 2021 | -14.49 Mn |
| Sep 30, 2021 | -15.36 Mn |